Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis - Wikidata - awgldk - TriplyDB

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

http://www.wikidata.org/entity/Q24647406

about

Evaluation of a multiple sclerosis cluster among nurses in an inpatient oncology ward Role of immunosuppressive therapy for the treatment of multiple sclerosis Systolic blood pressure variability and lower extremity amputation in a non-elderly population with diabetes.Disease-modifying agents in multiple sclerosis.Promising treatments of tomorrow for multiple sclerosis.High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases High-dose cyclophosphamide without stem cell rescue for the treatment of refractory Behcet's disease Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America.Repeated treatment with high dose cyclophosphamide for severe autoimmune diseases Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.Diagnosis and treatment of multiple sclerosis in pediatric and adolescent patients: current status and future therapies.Pathogenic mechanisms and experimental models of multiple sclerosis.Hematopoietic SCT for the treatment of multiple sclerosis.High-dose chemotherapy and multiple sclerosis.Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.Management of children with multiple sclerosis.Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.Therapeutic management of severe relapses in multiple sclerosis.Clinical impact of HLA class I expression in rectal cancer.High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies.Characterising aggressive multiple sclerosis.Medication Treatment in Multiple Sclerosis

P2860

Q23912471-90C9C759-1898-4DE6-826E-E9012AAEC73D Q26827467-E77AFA87-0D4D-483C-ACC7-48CFC7FB8BB8 Q30277672-C3ACF92A-EAB7-4CBB-A1E3-2B37F2A0B9F2 Q33670940-B990BBA3-16E0-471C-97AE-42E16BEE81FC Q33670947-7BC4EEAF-340F-4A7C-B0F1-06CE8052E6EB Q33747331-E860BDB1-1084-4E95-B061-A869A4D2AADB Q33965239-6E82EF05-0B72-4297-904B-11EF43B18315 Q34409273-66B6E01C-D8F9-4147-BD79-012E4BF2936D Q34478828-BCA57879-A5D3-4D04-B2AA-C87BD31835BA Q34922742-56995343-5830-4730-8A21-8C5BBD9F1F7F Q34986999-5B3BC878-6B12-4B6C-A0D1-BB48A93856AA Q35322297-55294D32-0540-4EB0-BEE6-EA55006F7604 Q35588410-7A22301A-817C-47AE-A1A4-69D1B3E50765 Q36562866-6468E36C-8CF4-4525-BC04-BFF1F233E159 Q36730633-BDA08FCE-8B9B-40E4-BE87-DDEEEED6CAD1 Q37052797-58F27342-28AD-400B-ACE7-1DAAC66C0187 Q37124529-77588160-028C-4D54-9BC5-5E4AF269C1FB Q37562166-43A839A6-3D7D-4048-839F-05FD6044AC95 Q37728003-C470EEAD-D585-4E33-B10D-2981DF9E5393 Q37778984-9115C8C7-70E5-4B4F-A0F5-5DF08E6596A8 Q37822255-2A73CAD9-E31F-4575-AC8D-79E586072D48 Q37851885-DFEEB01D-2AE5-4EAF-A3E9-55AC69A8E249 Q38002113-64C76B19-6997-40E3-9317-94FCDBD74753 Q38051577-AFD9FD69-3D31-4750-B45A-9A7DDE9CF705 Q38946338-83AAFAAA-9A26-47D1-BF1B-0B8601F2F402 Q39026942-4DE89B9C-9104-4B45-A97C-2B7FF26F9A4D Q40173498-B84426C7-087A-4B8A-8D67-6B48A5DFD367 Q41814408-7F9576C0-4ADD-49DC-9F4B-AC7D0FE4B710 Q45145307-E5AAECF4-8313-46E3-944A-33727C7529F2 Q57083576-2463C5A6-2DF4-4EA8-B71E-EC486D9C1A9F

P2860

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis

http://www.wikidata.org/entity/Q24647406

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Reduction of disease activity ...... aggressive multiple sclerosis

@ast

Reduction of disease activity ...... aggressive multiple sclerosis

@en

Reduction of disease activity ...... aggressive multiple sclerosis

@nl

type

label

Reduction of disease activity ...... aggressive multiple sclerosis

@ast

Reduction of disease activity ...... aggressive multiple sclerosis

@en

Reduction of disease activity ...... aggressive multiple sclerosis

@nl

prefLabel

Reduction of disease activity ...... aggressive multiple sclerosis

@ast

Reduction of disease activity ...... aggressive multiple sclerosis

@en

Reduction of disease activity ...... aggressive multiple sclerosis

@nl

P1433

Q24647406-FC46D642-758E-49B7-A3E7-205E2D282501

P1476

Q24647406-B2256E85-2636-47CF-BD48-F2FBCAC680C9

P2093

Q24647406-14B430D0-2D3E-4EA2-854D-EA7DC49831C6

Q24647406-14E17054-2BD3-4F6E-B420-56546A710C7E

Q24647406-3D8A5187-7F25-4F02-B296-403E779DCD3B

Q24647406-5D735BD0-C3DD-4C4F-8E8C-DF173F14E031

Q24647406-627422BD-BCB1-4757-B570-5975118CF5AB

Q24647406-64696F6B-28EC-4298-B984-F5CBE5F93D69

Q24647406-70FB0775-67BC-4336-A4BA-73EDE8805933

Q24647406-7DC75D85-82D2-4220-B928-AC02E34BD9FF

Q24647406-915CE3A5-873F-483E-B1A2-CB7482C0D5AE

Q24647406-9F0AE15C-E4F4-4A79-A36E-6DC3D50A8DD9

P2860

Q24647406-1D6185B9-04EC-44CA-A666-FBAA4296B7CC

Q24647406-3A6A4ACA-FD59-4530-9F39-2B925F378EDB

Q24647406-557C117F-BFA2-425B-AE74-C62D5E8183BB

Q24647406-6A129DF3-D9CE-4D83-9347-80E2B6E3BACB

Q24647406-6F8A9ADE-D6A9-49A6-A2EC-F29A4DE0B50D

Q24647406-7B3AE971-2C84-41F5-A211-740C97F924CA

Q24647406-7C416EE7-513E-491A-B19F-A2EBFA62EDD0

Q24647406-82BE87BF-F639-4FE5-99C3-51F145F392EF

Q24647406-8685BF48-2FE4-4EB8-8D17-B48155A728B5

Q24647406-87D55F48-AC17-40C6-B35F-7B8E744FBF78

P304

Q24647406-67D0E919-5CFF-45B4-99F5-C6F7D7012DD9

P31

Q24647406-D01FB7C7-C9B2-4839-97A4-8427A64D7690

P356

Q24647406-7A70CDDA-221A-4B62-B996-DEB45F33AB7B

P407

Q24647406-5D49057D-6777-41BA-BCE3-4C954C2BBB47

P433

Q24647406-1BA50EB2-A091-492D-BAD1-B4D15920D749

P478

Q24647406-4E94841A-4EB7-4D57-A313-569CC03FFB56

P50

Q24647406-B24901C9-C752-41B2-8263-326ED0FACA7D

P577

Q24647406-F403F081-3275-4C64-9209-83046F342A1C

P5875

Q24647406-01CE7F14-BFAD-4668-9D63-AA28927EC564

P698

Q24647406-D565365D-2076-4789-AC08-315539C6B5D8

P921

Q24647406-28470C7C-3ECE-4554-BF48-32D6F61AE5CA

Q24647406-E1D278B7-A90A-4F20-B606-D01865C8DEEA

P932

Q24647406-005D50BF-AD43-464E-AEC8-C0397FDEFF88

P356

ARCHNEUROL.65.8.NOC80042

P1433

P1476

Reduction of disease activity ...... aggressive multiple sclerosis

@en

P2093

Adam I Kaplin

http://www.w3.org/2001/XMLSchema#string

Avindra Nath

http://www.w3.org/2001/XMLSchema#string

Benjamin M Greenberg

http://www.w3.org/2001/XMLSchema#string

Carlos A Pardo

http://www.w3.org/2001/XMLSchema#string

Carrilin Trecker

http://www.w3.org/2001/XMLSchema#string

Chitra Krishnan

http://www.w3.org/2001/XMLSchema#string

Daniel B Drachman

http://www.w3.org/2001/XMLSchema#string

David M Yousem

http://www.w3.org/2001/XMLSchema#string

Douglas A Kerr

http://www.w3.org/2001/XMLSchema#string

Dzung L Pham

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis

Volumetric neuroimage analysis extensions for the MIPAV software package

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

Revised estimate of the prevalence of multiple sclerosis in the United States.

Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis

High-dose therapy for autoimmune neurologic diseases.

Aplastic anaemia.

Chronic nontraumatic diseases of the spinal cord.

Autologous stem cell transplantation in progressive multiple sclerosis--an interim analysis of efficacy.

P304

1044-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.65.8.NOC80042

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Peter A Calabresi

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5315202

http://www.w3.org/2001/XMLSchema#string

P698

18541787

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

2574697

http://www.w3.org/2001/XMLSchema#string